"Around the world, the treatment of patients with inflammatory diseases, such as rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis and Crohn's disease, has been transformed by the availability of REMICADE," said Robert J. Spiegel, M.D., chief medical officer and senior vice president, Schering-Plough Research Institute. "Schering-Plough is committed to bringing the benefits of REMICADE, with its proven efficacy and rapid onset of action, to relieve the suffering of patients with these chronic inflammatory conditions."
Important firsts for REMICADE include:
-- In August 1998, REMICADE was approved on an accelerated basis for the
acute treatment of moderate-to-severe Crohn's disease in patients who
have had an inadequate response to conventional therapy and
fistulizing disease. This approval made REMICADE the first TNF-alpha
inhibitor available in the U.S.
-- In August 1999, REMICADE became the first TNF-alpha inhibitor approved
in the European Union (EU) for the short-term treatment of severe,
active Crohn's disease and fistulizing, active Crohn's disease in
patients who have not responded to conventional therapy.
-- In December 2001, REMICADE became the first TNF-alpha inhibitor
approved in Japan for the treatment of moderate-to-severe Crohn's
-- In February 2002, REMICADE became the first TNF-alpha inhibitor
indicated in the U.S. to improve physical function in patients with
moderate to severe RA who have had an i
|SOURCE Centocor, Inc.|
Copyright©2007 PR Newswire.
All rights reserved